Related Experiment Video
Updated: May 5, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy
1The Third Division, Department of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan.
Insights
Digitalis-like immunoreactive substances were elevated in the plasma and heart cells of hypertrophic cardiomyopathy patients. These substances may be linked to pressure overload and affect cardiac cell function.
Area of Science:
- Cardiology
- Biochemistry
- Immunohistochemistry
Background:
- Digitalis-like immunoreactive substances (DLIS) are implicated in hypertension and heart failure.
- Limited data exists on DLIS in hypertrophic cardiomyopathy (HCM).
Purpose of the Study:
- To investigate the presence and significance of DLIS in plasma and myocardial tissue of HCM patients.
Main Methods:
- Fluorescence polarization immunoassay for plasma DLIS quantification.
- Immunohistochemical analysis of endomyocardial biopsy specimens using anti-digoxin antibody.
- Correlation analysis with clinical parameters and ultrastructural localization.
Main Results:
- Elevated plasma DLIS (>0.2 ng/mL) found in 22.2% of non-obstructive and 38.4% of obstructive HCM patients.
- DLIS detected heterogeneously in cardiocytes, localized to sarcolemma, T-tubules, and Z-bands.
- Plasma DLIS correlated with left atrial dimension and cardiac index in non-obstructive HCM; correlated with myocardial DLIS and LV end-diastolic pressure in obstructive HCM.
Conclusions:
- Increased DLIS in plasma and cardiocytes of HCM patients, potentially due to pressure/volume overload.
- DLIS may interact with the sarcolemma and be transported intracellularly within cardiocytes.
Aims:
Although increased digitalis-like immunoreactive substances have been found in cases of hypertension and heart failure, no information is available about digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy. We investigated digitalis-like immunoreactive substances in the plasma and biopsied specimens of patients with hypertrophic cardiomyopathy.
Methods And Results:
In 40 patients with hypertrophic cardiomyopathy (27 with the non-obstructive type and 13 with the obstructive type), the plasma concentration of digitalis-like immunoreactive substances was studied by fluorescence polarization immunoassay. Right ventricular endomyocardial biopsy specimens were analysed immunohistochemically, using a monoclonal antibody against digoxin. An increase in digitalis-like immunoreactive substances of more than 0.2 ng. ml(-1)in plasma was found in six of 27 patients with non-obstructive hypertrophic cardiomyopathy (22.2%) and five of 13 with obstructive hypertrophic cardiomyopathy (38.4%). Under light microscopy, positive staining against the antibody was observed heterogeneously on some cardiocytes. In non-obstructive hypertrophic cardiomyopathy, digitalis-like immunoreactive substances in the plasma correlated with the left atrial dimension and inversely with the cardiac index. In obstructive hypertrophic cardiomyopathy, plasma and myocardial digitalis-like immunoreactive substances were positively correlated; they also correlated with left ventricular end-diastolic pressures. Under electron microscopy, digitalis-like immunoreactive substances were detected at the sarcolemma in the free wall, T-tubules, intercalated discs and Z-bands of cardiocytes.
Conclusions:
Increased digitalis-like immunoreactive substances in plasma and cardiocytes, which may have been caused by pressure and/or volume overload, were found in patients with hypertrophic cardiomyopathy. Digitalis-like immunoreactive substances may act on the sarcolemma of cardiocytes and be transported into the cytoplasm.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

